Table 1:
Demographics of the cohort (n = 86).
| Variable | Values |
|---|---|
|
| |
| Demographics | |
| Age (years) | 2.7 [0.4, 12] |
| Assigned female sex (%) | 33 (39) |
| Stunted (height < 5%ile)(%) | 18 (21) |
| Weight for length < 5%ile (%) | 9 (10) |
|
| |
| Co-morbid conditions (%) | |
| Chronic kidney disease | 3 (3) |
| Chronic liver disease | 6 (7) |
| Immunocompromised | 17 (20) |
| Oncologic | 13 (15) |
| Stem cell transplant | 2 (2) |
|
| |
| Site of infection (%) | |
| Lung | 57 (66) |
| Abdomen | 20 (23) |
| Other | 9 (10) |
|
| |
| Presumed type of infection (%) | |
| Bacterial | 35 (41) |
| Viral | 23 (27) |
| Fungal | 3 (3) |
| Culture negative | 25 (29) |
|
| |
| Severity of illness | |
| PELOD-2 | 6 [4, 8] |
| pSOFA | 8 [6, 11] |
| Vasopressors (%) | 76 (88%) |
| Vasopressor-inotrope score (n = 76) | 8 [5, 11] |
| Lactate (mmol/L) | 3.1 [2.4, 4.8] |
|
| |
| Ancillary therapies | |
| Corticosteroids | 38 (44) |
| IVIg | 10 (13) |
| Renal replacement therapy | 10 (13) |
|
| |
| PARDS | |
| PARDS within 96 hours of sepsis | 36 (42) |
| Time to PARDS (hours) | 4 [2, 12] |
|
| |
| 28-day mortality | 20 (23) |